Neurocrine Biosciences: all 121 studies

Page 1 of 2. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)Not yet recruitingNCT07850739Phase 2
• Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase InhibitorNot yet recruitingNCT07832383Phase 2
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years OldRecruitingNCT07536269Phase 2
• Observational Study of VYKAT™ XR in Patients With Prader-Willi SyndromeEnrolling by invitationNCT07450664
• Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaRecruitingNCT07365462Phase 2
• Evaluation of NBI-1117570 in Inpatient Adults With SchizophreniaRecruitingNCT07288333Phase 2
• An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current ManiaRecruitingNCT07288320Phase 2
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaRecruitingNCT07227818Phase 3
• A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT07196501Phase 3
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaRecruitingNCT07114874Phase 3
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 4
• NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaRecruitingNCT07105098Phase 3
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06966401Phase 3
• NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaRecruitingNCT06963034Phase 3
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06963021Phase 3
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06911112Phase 3
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06786624Phase 3
• Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in CanadaEnrolling by invitationNCT06312189Phase 3
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4Results posted
• Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepTerminatedNCT05301894Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDDCompletedNCT05165394Phase 2Results posted
• Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal HyperplasiaCompletedNCT05063994Phase 3Results posted
• Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)TerminatedNCT04873869Phase 2Results posted
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)Active, not recruitingNCT04806451Phase 3Results posted
• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepCompletedNCT04625101Phase 2Results posted
• Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal HyperplasiaActive, not recruitingNCT04490915Phase 3Results posted
• A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy ParticipantsCompletedNCT04234672Phase 1Results posted
• Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseCompletedNCT04102579Phase 3Results posted
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal HyperplasiaCompletedNCT04045145Phase 2Results posted
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaCompletedNCT03891862Phase 4Results posted
• A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)CompletedNCT03792672Phase 1Results posted
• Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette SyndromeTerminatedNCT03732534Phase 2Results posted
• A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy ParticipantsCompletedNCT03706469Phase 1Results posted
• The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineCompletedNCT03698331Phase 4Results posted
• Phase 1 Study of TAK-831 in Healthy Adult Asian SubjectsCompletedNCT03687684Phase 1Results posted
• Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette SyndromeTerminatedNCT03530293Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal HyperplasiaCompletedNCT03525886Phase 2Results posted
• Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedNCT03444038Phase 2Results posted
• A Study of Diazoxide Choline in Patients With Prader-Willi SyndromeCompletedNCT03440814Phase 3Results posted
• A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of SchizophreniaCompletedNCT03382639Phase 2Results posted
• A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With SchizophreniaCompletedNCT03359785Phase 2Results posted
• Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedNCT03325010Phase 2Results posted
• A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable SchizophreniaCompletedNCT03319953Phase 2Results posted
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy ParticipantsCompletedNCT03224325Phase 1Results posted
• Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich AtaxiaCompletedNCT03214588Phase 2Results posted
• A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet FormulationCompletedNCT03101293Phase 1Results posted
• A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAHCompletedNCT03062280Phase 3Results posted
• A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)CompletedNCT02959892Phase 1Results posted
• Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette SyndromeCompletedNCT02879578Phase 2Results posted
• Comparison of Pharmacokinetics of Infacort® Versus Immediate-release HydrocortisoneCompletedNCT02777268Phase 1Results posted
• Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics StudyCompletedNCT02748694Phase 1Results posted
• Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive DyskinesiaCompletedNCT02736955Phase 3Results posted
• Extension Study for Patients Entered Into Study Infacort 003CompletedNCT02733367Phase 3Results posted
• Treatment of Adrenal Insufficiency in ChildrenCompletedNCT02720952Phase 3Results posted
• Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral AdministrationCompletedNCT02716987Phase 1Results posted
• Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal HyperplasiaCompletedNCT02716818Phase 3Results posted
• Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette SyndromeCompletedNCT02679079Phase 2Results posted
• Safety and Efficacy Study of NBI-98854 in Adults With Tourette SyndromeCompletedNCT02581865Phase 2Results posted
• A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy ParticipantsTerminatedNCT02566759Phase 1Results posted
• TAK-653 Escalating Single and Multiple Dose Study in Healthy ParticipantsCompletedNCT02561156Phase 1Results posted
• Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting OnlyCompletedNCT02408068Phase 1Results posted
• Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02405091Phase 3Results posted
• A Phase 3 Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02274558Phase 3Results posted
• An Investigational Study of HydrocortisoneCompletedNCT01960530Phase 1Results posted
• Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAHCompletedNCT01735617Phase 2Results posted
• NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaCompletedNCT01733121Phase 2Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)CompletedNCT01688037Phase 2Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 2Results posted
• Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal HyperplasiaCompletedNCT00519818Phase 1/2Results posted
• Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years OldActive, not recruitingNCT07187375Phase 2
• A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderCompletedNCT06267846Phase 2
• Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromeCompletedNCT05701774Phase 3
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for SchizophreniaTerminatedNCT05654870Phase 3
• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaCompletedNCT05545111Phase 2
• An Open-Label Study of Diazoxide Choline in Patients With Genetic ObesitiesWithdrawnNCT05532020Phase 2
• Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset SeizuresTerminatedNCT05493293Phase 2
• Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEETerminatedNCT05226780Phase 2
• Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal InsufficiencyCompletedNCT05222152Phase 2
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyCompletedNCT05206513Phase 3
• Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)CompletedNCT05203341Phase 2
• Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaTerminatedNCT05182476Phase 2
• A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset SeizuresCompletedNCT05159908Phase 2
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaCompletedNCT05110157Phase 3
• Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential TremorCompletedNCT04880616Phase 2
• Opicapone Treatment Initiation Open-Label StudyCompletedNCT04787965
• Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseCompletedNCT04400331Phase 3
• PWS Outcomes Assessment StudyCompletedNCT04102839
• An Open-Label Study of DCCR Tablet in Patients With PWSWithdrawnNCT04086810Phase 3
• Observational, Long-term Extension Study for Participants of Prior VY-AADC01 StudiesCompletedNCT03733496
• Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal PeriodCompletedNCT03714373Phase 3
• VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)CompletedNCT03562494Phase 1
• Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement TherapyWithdrawnNCT03532022Phase 3
• A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.CompletedNCT03496870Phase 1
• A Study of Chronocort® Versus Cortef ® in Healthy Adult Male SubjectsCompletedNCT03343327Phase 1
• A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female SubjectsCompletedNCT03311932Phase 1
• Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral AdministrationCompletedNCT03178214Phase 1
• Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseCompletedNCT03065192Phase 1
• Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic AgentsStatus unknownNCT03062033
• A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort FormulationsCompletedNCT03051893Phase 1
• An Open Label Study in Healthy Volunteers to Compare Chronocort® to HydrocortisoneCompletedNCT03019614Phase 1

← Neurocrine Biosciences overview and focus areas